Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-
based methods being considered the gold standard for drug susceptibility testing, molecular …

Drug-resistant tuberculosis (TB) is estimated to cause 13% of all antimicrobial resistance-
attributable deaths worldwide and is driven by both ongoing resistance acquisition and …

Background Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up.
People at risk of weak tuberculosis drug regimens are a priority for novel drug access …

Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a
relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb) …

Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for
treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the …

Introduction Several decades of antitubercular drug discovery efforts have focused on novel
antitubercular chemotherapies. However, recent efforts have greatly shifted toward …

Mycobacterium tuberculosis has acquired drug resistance to all drugs that have been used
against it, including those only recently introduced into clinical practice. Compared to other …

Background Emerging resistance to bedaquiline (BDQ) threatens to undermine advances in
the treatment of drug-resistant tuberculosis (DRTB). Characterizing serial Mycobacterium …

Objectives The aim of the study was to update the classification of drugs used in multidrug-
resistant tuberculosis (MDR-TB) regimens. Group A drugs (fluoroquinolones, bedaquiline …

Studies have shown that variants in bedaquiline-resistance genes can occur in isolates from
bedaquiline-naive patients. We assessed the prevalence of variants in all bedaquiline …